LIFECORE BIOMEDICAL, INC. \DE\ LFCR
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $128.9M at a -30.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.232 |
| Retained earnings / assets | -0.858 |
| EBIT / assets | -0.072 |
| Equity / liabilities | 0.007 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| LFCR | LIFECORE BIOMEDICAL, INC. \DE\ | 3/9 | -1.75 | — | +0.5% |
| XNCR | Xencor Inc | 3/9 | 2.23 | — | +13.7% |
| ASRT | Assertio Holdings, Inc. | 2/9 | -6.37 | — | -5% |
| GYRE | GYRE THERAPEUTICS, INC. | 3/9 | 4.52 | 71 | +10.2% |
| KPTI | Karyopharm Therapeutics Inc. | 2/9 | — | — | +0.6% |
| URGN | UroGen Pharma Ltd. | 1/9 | -15.59 | — | +21.4% |
| ELTP | ELITE PHARMACEUTICALS INC /NV/ | 6/9 | 7.73 | 9.5 | +77.1% |
About LIFECORE BIOMEDICAL, INC. \DE\
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
FAQ
Is LFCR financially healthy?
LIFECORE BIOMEDICAL, INC. \DE\'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does LFCR pay a dividend?
No, LIFECORE BIOMEDICAL, INC. \DE\ does not currently pay a dividend.
How profitable is LFCR?
In FY2025, LIFECORE BIOMEDICAL, INC. \DE\ had a net margin of -30.0% and a return on equity of -2898.0%.
Is LFCR overvalued or undervalued?
LIFECORE BIOMEDICAL, INC. \DE\ trades at about 14.5× trailing earnings — below its 10-year norm (10-year range 15.5×–937.0×, median 17.6×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for LFCR?
The average Wall-Street price target for LIFECORE BIOMEDICAL, INC. \DE\ is $6.83, about 43.3% above the recent price, from 3 analysts (consensus: buy).
Is LFCR a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on LIFECORE BIOMEDICAL, INC. \DE\: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-05-25. Facts plus Stocktoria's own computed scores — not investment advice.